Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in prurigo nodularis
NCT04202679Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of dupilumab in prurigo nodularis (PN), sponsored by Sanofi. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT04202679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202679.